Allogene Therapeutics reports Q1 EPS (32c), consensus (43c)
"We are very pleased with our ability to accelerate the research and development activities for both ALLO-501 and ALLO-715," said David Chang, M.D., Ph.D., President, CEO and Co-Founder of Allogene. "Our focus from day one has been on the acceleration of AlloCAR T therapy to enable an "off-the-shelf" CAR T therapy for patients. In May 2018, we started Allogene with approximately 40 employees. Today, we have over 150 employees, all dedicated to making AlloCAR T therapy a reality." An Investigational New Drug application has been submitted to the U.S. FDA for ALLO-715, a wholly-owned CAR T product candidate targeting B cell maturation antigen for relapsed/refractory multiple myeloma. The Company remains on track to initiate a Phase 1 trial in 2019.